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Abstract 
Soluble amyloid-β (Aβ) is considered to be a critical component in the pathogenesis of 
Alzheimer’s disease (AD). Evidence suggests that these non-fibrillar Aβ assemblies are 
implicated in synaptic dysfunction, neurodegeneration and cell death. However, 
characterization of these species comes mainly from studies in cellular or animal 
models, and there is little data in intact human samples due to the lack of adequate 
optical microscopic resolution to study these small structures. Here, to achieve super-
resolution in all three dimensions, we applied Array Tomography (AT) and Stimulated 
Emission Depletion microscopy (STED), to characterize in postmortem human brain 
tissue non-fibrillar Aβ structures in amyloid plaques of cases with autosomal dominant 
and sporadic AD.  Ultrathin sections scanned with super-resolution STED microscopy 
allowed the detection of small Aβ structures of the order of 100 nm. We reconstructed a 
whole human amyloid plaque and established that plaques are formed by a dense core 
of higher order Aβ species (~0.022µm3) and a peripheral halo of smaller Aβ structures 
(~0.003µm3). This work highlights the potential of AT-STED for human 
neuropathological studies.  
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Introduction 
Amyloid-β (Aβ) aggregation is believed to be a key initial pathophysiological event in 
Alzheimer’s disease (AD). Several in vitro and in vivo studies have shown that, under 
certain conditions, Aβ peptides are able to form small soluble oligomers that grow into 
protofibrils and finally into dense insoluble structures that accumulate in the brain in 
form of extracellular β-amyloid plaques (1- 3). There is growing evidence that soluble 
Aβ species are more toxic than fibrillar Aβ in causing neuronal loss and synaptic 
dysfunction (4-7). Aβ oligomers can induce neuronal and synaptic damage through 
different mechanisms, such as inhibition of hippocampal long-term potentiation (8), 
inhibition of exocytosis by impairing SNARE complex formation (9), deregulation of 
NMDA-mediated calcium influx triggering synaptic collapse (10) or the formation of 
membrane pores causing permeabilization and inducing neuronal death (11, 12). 
The majority of cases of AD are sporadic (SAD) but in ~1% of cases the disease 
segregates with an autosomal dominant pattern (ADAD) and an early age of onset (13, 
14). ADAD is caused by mutations in the amyloid precursor protein (APP) or in the two 
presenilin (PSEN1 and PSEN2) genes (15, 16). Different studies have demonstrated 
that these mutations cause a chronic increase in the relative or absolute production of 
the 42-aa form of Aβ peptide (Aβ42) leading to the formation of oligomeric Aβ, fibrillar 
Aβ deposition and neurodegeneration (15, 17). In contrast, the mechanisms underlying 
Aβ accumulation in SAD patients are far more complex. The main hypothesis to explain 
Aβ deposition in SAD is the existence of a chronic imbalance between Aβ production 
and clearance as a result of aging and other risk factors (17-22). 
Although it is often assumed that the soluble Aβ species are the most toxic, the main 
properties such as size, morphology, structure and stability in human brain remain 
under study (23-26). The majority of available data is based on experiments that used 
synthetic Aβ42 oligomers on cell cultures or animal models that overexpress mutant 
APP (5, 6, 27-30) and few studies have investigated the role of non-fibrillar Aβ in intact 
human brain samples (31- 39).  
The study of small structures such as non-fibrillar Aβ species in human brain samples 
has been challenging due to the limited resolution of immunohistochemistry using 
conventional microscopy. The lowest resolution obtained with optical microscopy is 200 
nm, thus precluding any detailed characterization of those species. A recent study 
showed that the combination of new technologies such as focused ion beam milling 
and scanning electron microscopy (FIB/SEM) plus computational tools can be applied 
for the study of human amyloid plaques or synapses in the AD brain (40). The use of 
hyperspectral Raman imaging has been also applied for the study of the biochemical 
components and β-sheet content of amyloid plaques and their surroundings (41). In 
light microscopy, other techniques are also emerging for the study of small structures in 
brain tissue.  One example is array tomography (AT), a technique that combines 
ultrathin sectioning of the tissue to increase the axial resolution with 
immunofluorescence, allowing quantitative analysis of high-resolution and large-field 
volumetric imaging of different specimens, such as synapses or pathological 
aggregates. (42). AT has demonstrated the ability to resolve Aβ synaptic deposits in 
AD brains (6). Additionally, in the super-resolution (SR) fluorescence microscopy 
domain, Stimulated Emission Depletion (STED) microscopy is a technique that 
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combines a high resolution confocal microscope with a high power donut-shaped 
depletion laser. The STED configuration uses the excitation and depletion lasers 
simultaneously increasing the lateral resolution by reducing the emission area 
selectively depleting the fluorescent molecules under the donut-shaped beam (43, 44).  
In the present work, we propose a new tool to study the nanometric neuropathology of 
neurodegenerative diseases by combining ultrathin sections used in AT scanned with 
super-resolution STED microscopy. Applying AT-STED, we investigate the nanoscale 
architecture of non-fibrillar Aβ structures in human amyloid plaques. We also 
investigated the load and size of these non-fibrillar Aβ entities in post-mortem human 
brain tissue in ADAD (PSEN1 mutation carriers) and early-onset sporadic AD (eoSAD) 
patients. 
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Results 
Conventional immunohistochemistry reveals no differences between ADAD and 
eoSAD cases in total or non-fibrillar Aβ. 
We included a group of 14 patients with eoSAD, 10 patients with ADAD carrying a 
PSEN1 mutation and 9 healthy controls. Demographic, clinical and genetic data are 
shown in Supplementary Table S1. Detailed neuropathological data of the cases is 
shown in Supplementary Table S2. As expected, eoSAD cases had a later age of 
onset and death and higher frequency of the APOEε4 allele compared to ADAD cases. 
We employed conventional immunohistochemistry of consecutive sections to examine 
the differences in total and non-fibrillar Aβ immunoreactivity (using the NAB61 
antibody) between ADAD, eoSAD and control cases. We found higher amyloid load in 
ADAD and eoSAD cases (p<0.001) compared to controls but without differences 
between the AD groups (Fig. 1). 
Improving spatial and axial resolution with AT and STED  
We next investigated the potential of combining two microscopy techniques to 
investigate non-fibrillar Aβ structures in human AD brains. AT provides improved 
resolution in the axial plane by obtaining 70nm thick tissue sections. Due to the special 
fixation and tissue processing requirements for this method, the availability of samples 
for this type of studies is limited. In order to obtain nanometric resolution in the lateral 
directions here we combined AT with STED. STED microscopy combines a high 
resolution confocal microscope with a high power depletion laser. This laser has been 
engineered to obtain a donut-shaped focal-spot and it is scanned simultaneously with 
the excitation laser. This configuration enables stimulated depletion emission on the 
molecules under the donut-shaped beam. Thus, the emitted light in this outer region of 
the excitation beam is forced to emit at the wavelength of the STED laser. Using 
adequate spectral filtering, the light generated in the center of the donut is then 
collected for analysis which is determined by the power of the STED laser. We 
acquired images of amyloid-β plaques with an STED microscope using both confocal 
and STED configurations. The combination of AT and the settings of STED used in this 
experiment yielded a minimum effective voxel size of 70x100x100nm. This voxel size 
allowed us to resolve smaller non-fibrillar Aβ structures in comparison with using AT 
alone (Fig. 2). A 3D reconstruction of a full amyloid β plaque of ~50µm of diameter is 
shown in Figure 2. The use of AT-STED microscopy provided increased resolution of 
the amyloid-β aggregates compared with high resolution confocal microscopy. A tool 
published by Merino et al. (44), enables to obtain an objective parameter, in which the 
sample is also considered, that can be used to determine the optimal settings for the 
STED image acquisition. Using this tool, we demonstrated an extension in the 
frequencies that allowed identifying objects down to 110nm; in contrast, with AT alone 
the size of the smallest structure detected in the lateral plane was 220nm.  
 
The combination of AT and STED allows the identification of smaller non-fibrillar 
Aβ structures 
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We applied AT-STED to 368 consecutive sections to obtain a detailed architecture of a 
whole human amyloid β plaque at a nanoscale resolution (Fig. 3 video1).  
We next selected randomly amyloid β plaques (n=13) from two AD cases (one ADAD 
and one SAD) and captured images using both confocal and STED configurations to 
examine the size and distribution of NAB61-immunoreactive Aβ structures (a total of 
18.000 objects). We also immunostained for neurofilaments to visualize the neuronal 
structures around the plaque (Fig 4. A,D). We divided the objects into three categories: 
small (<0,006 µm3; red), medium (>0,006<0,015 µm3; green) and large (>0,015 µm3; 
blue). We obtained a distinguished dense core formed by higher order Aβ structures 
(blue) and a halo of medium and small non-fibrillar Aβ entities (green and red) 
surrounding the plaque (Fig. 4). Using the combination of AT-STED compared to AT 
alone, we observed an increase of all Aβ structures (Fig. 4). Quantitative analyses of 
the distributions confirmed that the combination of AT-STED allows detecting smaller 
Aβ structures compared with AT alone (Fig. 4).   
 
Higher levels of non-fibrillar Aβ structures in ADAD than in SAD  
Taking advantage of the enhanced resolution, we applied AT-STED to investigate 
potential differences in non-fibrillar Aβ structures between an ADAD and a SAD case. 
We stratified the objects depending on the presence of PSEN1 mutation and analyzed 
the distribution, size, proportion and quantity of non-fibrillar Aβ structures (total of 
~18.000 objects). We observed an increase in the number of Aβ structures for all sizes 
(small, medium and large) in the ADAD case compared with the SAD case (p<0.001) 
(Fig. 5).  
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Discussion 
This study combines two microscopy techniques to examine non-fibrillar Aβ structures 
in human amyloid plaques in the brain. Using this enhanced resolution we demonstrate 
that the distribution of Aβ assemblies consists of a dense core of higher order Aβ 
species surrounded by a peripheral halo of small Aβ structures. The combination of AT 
and STED allowed detecting non-fibrillar Aβ forms of at least 100nm. Finally, we 
provide preliminary evidence of higher levels of Aβ structures in an ADAD case 
compared to a SAD case. 
Several studies have focused on the characterization of Aβ oligomers in AD (6, 45-47). 
Electrophysiological and biochemical experiments have suggested that soluble Aβ 
oligomers correlate with disease severity (48, 49) and that there is an inverse 
correlation between the size of Aβ assemblies and their toxicity in multiple in vitro and 
in vivo models (3, 6, 7). The potential structure, size, conformation, aggregation and 
induction of neurotoxicity of Aβ oligomers in AD pathogenesis has been thoroughly 
investigated through the application of several advanced technologies such as ion 
mobility-based mass spectrometry (25), atomic force microscopy (50, 51), solid-state 
nuclear magnetic resonance (52) and X-ray microdiffraction (53). Other studies have 
used FIB/SEM to investigate the relationship between amyloid plaques and the 
synaptic organization in human AD brains (40).  
Here, we combined AT and STED to improve the resolution obtained with conventional 
confocal microscopy (x,y: 250nm and z: 700nm) and the detection of non-fibrillar Aβ 
structures in human amyloid plaques. AT achieves a resolution of 70nm on the axial 
plane, while STED microscopy can increase the lateral resolution. In our case the 
addition of STED increased the lateral resolution up to 100nm. This technique has 
been applied to investigate in detail the cellular mechanisms underlying dendritic spine 
plasticity (54, 55), glial processes (56) or α-synuclein synaptic aggregation (57) among 
others. Using the enhanced resolution of AT-STED we were able to reconstruct a 
whole human amyloid plaque and examined in detail the nanoscale distribution and 
size of the non-fibrillar Aβ species. AT-STED allows detection of Aβ structures of at 
least 100nm, an undetectable size range for immunohistochemical assays due to the 
resolution limit of light and confocal microscopes (~250nm) (43, 58). The study 
revealed that human amyloid plaques consist of a dense core of NAB61 large 
immunoreactive structures (~0.022µm3) and a peripheral halo of medium and small 
non-fibrillar Aβ entities (~0.01µm3 and ~0.003µm3 respectively). These results are in 
agreement with a study that used the AT technique to study NAB61 immunoreactivity in 
an animal model of AD (5). However, we were able to detect non-fibrillar Aβ structures 
2 times smaller using AT-STED in human tissue. 
In addition, we show preliminary evidence that non-fibrillar Aβ structures were 
increased in an ADAD case compared to a SAD case in human brain tissue. It is 
known that oligomeric Aβ accumulation induces neuronal cell loss (27), astrocytic 
dysfunction (59) and synaptic toxicity (6,33), and it is possible that higher levels of non-
fibrillar Aβ are a characteristic of ADAD and may be the reflection of abnormal APP 
processing (17). Interestingly, this result was not detectable in conventional 
immunoassays pointing out the importance of implementing super-resolution 
techniques for detailed neuropathological studies. 
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The strengths of this work are the inclusion of two microscopy techniques for the study 
of human brain samples; and the implementation of computational tools for image 
processing and analysis. The main limitations are the small sample size for AT-STED 
due to fact that the requirement of fresh tissue makes these samples extremely scarce. 
Second, we only used one antibody to detect non-fibrillar Aβ. However, in our hands 
specific antibodies for oligomeric Aβ suitable for human tissue are exceedingly rare and 
NAB61 has been extensively characterized (5, 33, 60). 
In conclusion, as a proof of concept our study shows that the combination of AT and 
STED can be successfully applied to investigate non-fibrillar Aβ structures in AD 
human brain. The obtained nanoscale architecture of human amyloid plaques reveals a 
dense core with a peripheral halo and we provide evidence of higher levels of non-
fibrillar Aβ species in ADAD compared to SAD. Additional studies are needed to further 
investigate the potential relevance of these assemblies in the pathogenesis of the 
disease. This new tool proposed opens an important door for the neuropathology field 
allowing the characterization of aggregates or structures at a nanometric scale as 
potential therapeutic targets.      
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Materials and methods 
Standard protocol approval and patient consent. We obtained written informed 
consent from all brain donors and/or next of kin for the use of brain tissue for research. 
The study was approved by the local ethics committee of Hospital de Sant Pau, 
Barcelona, Spain. All research was performed in accordance with relevant guidelines 
and regulations. 
Postmortem human brain samples. Brain samples for immunohistochemical assays 
were provided by the Neurological Tissue Bank (NTB) of the Biobanc-Hospital Clínic-
IDIBAPS and processed as previously described (61) and as internationally 
recommended (62). The study group consisted of 34 subjects: 10 patients with PSEN1 
mutations, 14 eoSAD patients with an age of onset < 65 years and a group of 9 healthy 
controls. Fresh brain tissue from one ADAD (PSEN1 G206D, age 63) and one SAD 
case (age 90) was processed for AT as previously described (57, 63) and included in 
our collection.  
Immunohistochemistry, image acquisition and analysis. Immunohistochemistry 
was performed on 5-μm-thick consecutive sections of occipital cortex on an automated 
stainer (DAKO Autostainer Plus; DAKO, Glostrup, Denmark) using the following 
primary antibodies: mouse monoclonal anti-amyloid beta clone 6F/3D (dilution 1:400, 
DAKO, Glostrup, Denmark) and mouse anti-NAB61 (dilution 1:250, a kind gift from 
Virginia Lee, University of Pennsylvania, Philadelphia, USA). Reaction was visualized 
by the EnVision+ system peroxidase procedure (DAKO, Glostrup, Denmark). Full-
section scans were obtained with Pannoramic MIDI II (3DHistech, Budapest, Hungary) 
using a 40x objective. Cortical grey matter of each case was manually delimitated with 
pannoramic viewer software (3DHistech, Budapest, Hungary). An adaptation of the 
algorithm previously described (64) was developed to quantify total Aβ and NAB61 
immunoreactivity with MATLAB software (The Math Works, Inc., Natick, MA, USA). 
Specifically, a colour deconvolution was used to split the channels and a mean local 
filter was then applied to segment the structures (Supplementary Figure S1). 
Array Tomography. Brain samples for AT were processed using previously described 
methods (57, 63). Briefly, 70nm-thick sections were obtained using an ultramicrotome 
(Leica Microsystems) equipped with an Ultra Jumbo Diamond Knife 35º (Diatome) from 
LR white embedded tissue blocks. The ribbons were stained as previously described 
(63) and incubated with Tris-Glycine solution 5’ at RT followed by a blocking of 
unspecific antigens with a cold water fish blocking buffer (Sigma-Aldrich) for 30 min. 
Sections were then incubated for 2 hours with the following primary antibodies: mouse 
anti-NAB61 (dilution 1:50, kindly provided by Virginia Lee, University of Pennsylvania, 
Philadelphia, USA) and rabbit anti-Neurofilament Light (dilution 1:50, #2837, Cell 
Signaling). After TBS washings, secondary fluorescent antibodies Alexa 488 and Alexa 
555 (dilution 1:50, Invitrogen) were applied for 30’. Sections were washed with TBS 
and samples were stained with Hoechst 33258 (dilution 1:100, Life Technologies) for 5 
min for nuclei visualization. Finally, coverslips were mounted on microscope slides with 
Immu-Mount (Fisher Scientific) mounting medium.  
STED and confocal image acquisition. The acquisition of confocal and STED images 
has been performed using a Leica STED CW microscope (Leica Microsystems). The 
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excitation wavelength was 488nm and the spectral detector window has been set from 
495nm to 588 nm. The objective used was a Leica HCX PL APO CS 100.0x STED with 
1.4 NA. The 592 nm STED laser was set to 85% and the detectors used were Hybrid 
detectors in photon counting mode. The scanning speed was 1000Hz per line and each 
acquisition has been obtained accumulating six times per line and averaging two 
acquisitions per image. Finally, these settings provided a set of images of 2048 x 2048 
with effective pixel dwell time of 5.9 µs.  
Image processing and analysis. For the analysis of AT images, MATLAB software 
(The Math Works, Inc., Natick, MA, USA) was used. Image stacks of each channel 
comprising all 70 nm consecutive sections were first registered using a rigid registration 
followed by an affine registration of a reference channel. Aligned sections were 
segmented using an automated mean local thresholding. Additionally, objects that were 
not in at least two consecutive sections or that were less than 3px were considered 
background and removed. After identification of three-dimensional structures, the 
density and size of individual entities were quantified. In order to perform the 3D 
visualization of the human amyloid plaque, the 2D images were stacked in a whole 3D 
reconstruction.   
Statistical analysis.  R software (version 3.2.5, www.r-project.org) was used to assess 
the statistical analysis. Due to the non-normal distribution of the data, non-parametric 
tests were applied. For immunohistochemical assays, Kruskal-Wallis with Dunn’s post 
testing were used to detect differences in NAB61 and total Aβ levels between groups 
and a Mann-Whitney test was used for the ratio. To assess the differences between the 
ADAD case and the SAD case, an unpaired Mann-Whitney test was used.   
Data availability: All data generated or analysed during this study are included in this 
published article (and its Supplementary Information files). 
 
 
. 
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Figures and video legends 
 
Figure 1. Quantification of total and non-fibrillar Aβ in ADAD and eoSAD cases. 
(A-I) Representative images of total Aβ and NAB61 immunoreactivity of ADAD, eoSAD 
and control cases. Strong immunoreactivity for both markers in consecutive sections 
from ADAD and eoSAD cases was found. Scale bar = 50 µm and 10 µm for inset. (J-K) 
Total Aβ and NAB61 densities were increased in both AD groups compared with 
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controls. (L) No differences were found in the ratio NAB61/total Aβ between ADAD and 
eoSAD. *** p<0.001 
 
Figure 2. Comparison of the resolution between AT-Confocal and AT-STED 
modalities. (A, G) Maximal projection of a 3D reconstruction of an amyloid beta plaque 
in AT-Confocal and AT-STED respectively. (B, H) Image of a single slice of the 
amyloid-β plaque. (C-F; I-L) insets. (M-N) Frequency domain representation of B and 
H. (O) Radial average of the frequency information for the AT-Confocal and AT-STED 
cases. (P-Q) Difference between of the radial frequency information between 
modalities. Green lines show the theoretical diffraction limit for 1.4NA objective.  
Figure 3 (video1). Nanoscale architecture of an entire human amyloid plaque 
using AT-STED.  Reconstruction of 368 consecutive sections of an amyloid plaque 
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from a SAD case. Zoom during the video shows the non-fibrilar Aβ structures better 
resolved in STED compared to confocal microscopy.      
 
Figure 4. Distribution and quantification of non-fibrillar Aβ structures using AT-
Confocal vs AT-STED. (A,D) Representative images of a human amyloid beta plaque 
and the surrounding neuronal structures (neurofilament light magenta) using (A) AT 
alone or (D) AT-STED. (B,E) Images of a segmented 2D projection of the Aβ plaque 
and (C,F) the respective 3D insets. Each color indicates a different Aβ structure’s size: 
large (>0,015 µm3; blue), medium (>0,006<0,015 µm3; green) and small (<0,006 µm3; 
red). Detection of a dense core formed by large Aβ structures and a halo around the 
plaque formed by medium and small Aβ entities.  Scale bar = 10 µm and 1 µm for the 
inset. (G) AT-Confocal and AT-STED distribution of NAB61 structures.  
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Figure 5. Non-fibrillar Aβ structures are increased in an ADAD case. (A-F) 
Representative images of non-fibrillar Aβ structures distribution and size identified in 
plaques of an ADAD (n=8) and a SAD (n=5) case using AT-STED. Neurofilament light 
protein (magenta) was stained to visualize the neuronal distribution around the 
plaques. Scale bar = 10 µm and 1 µm for the inset. (G) ADAD and SAD distribution of 
NAB61 structures number by size. Differences were found between both distributions 
(p<0.001). (H) All Aβ entities were significantly increased in ADAD compared to SAD 
case (p<0.001).  
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 SUPPLEMENTAL MATERIAL 
 
 
 
 
 
 
 
 
 
Supplementary Figure S1. Image processing pipeline. Whole slice scans are obtained 
and random regions of interest are manually delimitated. The application of an in-house 
algorithm allows two different analyses. 1) Quantification of total Aβ or NAB61 
immunoreactivity excluding amyloid angiopathy. 2) Quantification of soluble NAB61+ 
structures around plaques.        
 
 
 
 
Supplementary Table S1. Demographic, clinical and genetic data of eoSAD and 
ADAD patients. 
*Calculated without missing data (ADAD n=8 and eoSAD n=12). M: male; SD: standard 
deviation. 
 ADAD 
(N =10) 
eoSAD 
(N =14) 
p value 
Gender = M (%) 7 (70.0) 6 (42.9) 0.368 
Mean age at onset (mean (SD)) 43.80 (6.16) 51.36 (3.52) 0.001 
Mean age at death (mean (SD)) 54.90 (5.69) 60.79 (4.10) 0.007 
Mean disease duration  (mean (SD)) 11.10 (4.41) 9.43 (3.25) 0.296 
APOE ε4 allele carriers = n (%) 2 (25.0)* 8 (66.7)* 0.171 
  
Supplementary Table S2. Neuropathologic data of eoSAD and ADAD cases. 
 
CERAD: Consortium to Establish a Registry for Alzheimer's Disease; F: female; M: 
male; NF: neurofibrillary; PMI: post-mortem interval. 
 
Case # Mutation Gender Thal Aβ 
phase 
Braak NF 
stage 
CERAD Age at 
onset 
Age at 
death 
APOE 
genotype 
PMI 
(h) 
PSEN1 mutation carriers       
1 V89L M 5 V freq 45 54 23 
7,5 
2 V89L M 5 VI freq 48 57 23 9.5 
3 E120G M 5 VI freq 34 44 33 5.5 
4 M139T M 5 V freq 47 64 33 14.7 
5 M139T M 5 VI freq 48 57 33 15.2 
6 M139T M 5 VI freq 45 53 33 5.3 
7 M139T F 5 VI freq 38 48 23 5,25 
8 P264L F 5 VI freq 45 56 44 6 
9 P264L M 5 VI freq 53 60 34 7.2 
10 G206D M 5 VI freq 37 44 34 19.2 
Sporadic Early-onset AD 
11 - M 4 V freq 51 65 44 18 
12 - M 4 VI freq 52 65 33 8 
13 - M 4 VI freq 52 60 44 10,25 
14 - F 5 VI freq 51 60 33 5 
15 - M 5 VI freq 46 55 33 4,5 
16 - F 4 VI freq 50 63 33 6,5 
17 - F 5 VI freq 56 67 44 4 
18 - F 5 VI freq 54 62 44 6 
19 - F 5 VI freq 58 66 43 12,5 
20 - F 5 VI freq 52 57 43 4,5 
21 - F 5 VI freq 46 56 43 16,25 
22 - M 5 VI freq 47 57 43 10 
23 - F 5 VI freq 50 62 33 12,6 
24 - M 5 VI freq 54 56 - 14,16 
